Jan 06, 2025 by Bailey G. Salimes, CRTonline.org
Low-risk, trial-like patients undergoing surgical aortic valve replacement (SAVR) during the trial enrollment period have similar 30-day rates of mortality, but lower rates of stroke, compared with patients in the SAVR arm of the PARTNER 3 and Evolut Low Risk trials, a cross-sectional analysis shows.